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Summary: In the first part of the present study we compared the antigenicity of affinity-purified acetylcholine
receptors from the cell line TE671 and from human skeletal muscle. The reactivities of the two acetylcholine
receptor preparations showed a strong correlation (r = 0.96) in a radioimmunoassay using sera from myas-
thenia gravis patients. In additional functional studies, carbamylcholine stimulated cAMP production in
TE671 cells to 130%. This increase was even more pronounced when TE671 cells were grown in the presence
of dexamethasone. -Bungarotoxin completely blocked this carbamylcholine-induced cAMP increase. Using
the Ca2+ indicator, indo-1, it was shown that intracellular Ca2+ concentrations ([Ca2+]j) were elevated in
TE671 cells after stimulation with carbamylcholine. This effect was also completely blocked by oc-bungarotoxin.
To test the functional activity of autoantibodies against the acetylcholine receptor, TE671 cells were prein-
cubated with sera from myasthenia gravis patients. In one third of sera a significant inhibition of the agonist-
stimulated [Ca2+]i increase was detected, possibly caused by antibodies directed to functionally important
areas of the acetylcholine receptor. There was no correlation between the inhibition rate of [Ca2+]j and anti-
acetylcholine receptor antibody titres in these patient sera.
Introduction . '· n /< o\ ? · · * - -immunologically (1, 2). For immunological studies in
Autoantibodies direct against the human äcetylcho- myasthenia gravis these receptors are less useful be-
line receptor are known to play an important role in^ cause of their low cross-reactivity to human acetyl-
the pathogenesis of myasthenia gravis. However, iso^· choline receptor (3, 4). Therefore, human acetylcho-
lation of the target structure, the acetylcholine recep-' line receptor from amputated leg muscle tissue has
tor from human muscle tissue, is difficult and various usually been applied as autoantigen in different as-
preparations differ in their antigenicity. As an alter- says. However, the supply of human muscle is limited
native we isolated the acetylcholine receptor from the and more importantly, during the preparation human
human cell line TE671 and investigated its reaction muscle acetylcholine receptor is easily degraded (5,
with human autoantibodies immunologically and 6). The human TE671 cell line expresses significant
functionally. numbers of acetylcholine receptors and is therefore a
r™ . . . , t i- · . · „ .,- , useful alternative source for acetylcholine receptorThe nicotimc acetylcholine receptor, initially purified ,. ^,. „ ,. . ... „ , ., ,- , . J f · % . , . , , preparations. This cell line was initially described asirom electric organs of certain fish species has been , , „ , , . ,. , ,, A11. 0 ~ ,« , . , , . , . „ ' , · t, a human medulloblastoma line by McAllister & Gard-characterized biochemically, pharmacologically and /aN T. , ., . . , . , ,J9 K & J ner (7). It has recently been reported to have muscle
. like features, and probably originates from a human
') This work was supported by a grant from the Wilhelm- rhabdomyosarcoma cell (8). Luther & Lindstrom gen-
Sander-Stiftung and in part by SFB 263. erated cDNA probes specific for acetylcholine recep-
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tor subunits from TE671 cells, which show a complete
homology to nucleotide sequences described for hu-
man skeletal muscle type acetylcholine receptor su-
bunits (9).
In the present study we demonstrated a cross-activity
of myasthenia gravis patient sera with acetylcholine
receptor preparations from human muscle and from
TE671 cells.
Furthermore, TE671 and the neuroblastoma line
IMR32 (10), both of which express a-bungarotoxin
binding sites, were tested to determine whether these
α-bungarotoxin binding proteins represent functional
acetylcholine receptors. This was done by measuring
intracellular signal transduction, i. e. the increase in
cAMP and the increase in intracellular Ca2+ concen-
tration after stimulating cells with the acetylcholine
receptor-specific agonist carbamylcholine. Finally,
both cell lines were used to test whether autoantibod-
ies from myasthenia gravis patient sera (n = 11) mod-




IMR32 (CCL 127) and TE671 (HTB 139) cells were obtained
from the American Tissue Culture Cooperation (ATCC). Both
lines were grown in Dulbecco's modified Eagle's medium using
large cell culture flasks (Nunc; 850 ml). IMR32 medium was
supplemented with 0.1 volumes of fetal calf serum and 3.5 g/1
glucose. TE671 cells were grown in 0.05 volumes of fetal calf
serum supplemented medium in the presence or absence of 2.5
μιηοΐ/ΐ dexamethasone (Sigma). Both lines were grown in con-
fluent monolayers and removed mechanically before use.
Gel f i l t ra t ion of α-bungarotoxin b inding proteins
IMR32 and TE671 cells (5 χ ΙΟ8) were solubilized with 10 g/1
Triton X100 (Sigma) in 10 mmol/1 sodium phosphate buffer
(pH 7.2) for 1 h, by gently shaking, and ultracentrifuged at
4°C and 100 000 £ in a Kontron^ ultacentrifuge (Kontron
TGA-65; rotortype: 50 Ti) for 40 min. The supernatant was
filtered through glass wool and the resulting solubilized cell line
extracts were incubated with an excess (0.185 MBq) of [125I]ct-
bungarotoxin (Amersham & Buchler; IM-109) for approxi-
mately 16 h at 4 °C. Unbound ligand was removed by column
gel filtration, using a 30 χ 1.8 cm Sephadex G50 filled column
(Pharmacia). Radioactivity of various fractions was measured
using a gamma counter (Minaxi-gamma; Packard). Molecular
masses of [12SI]a-bungarotoxin binding proteins in the cell lys-
ates were determined by gel filtration, using defined standard
proteins (Sigma).
Affini ty chromatography of α-bungarotoxin binding
proteins
Lysates of IMR32 and TE671 cells (5 χ ΙΟ8) were prepared as
described above and incubated overnight with a-bungarotoxin-
coupled (21 Gel) Sepharose 4B (Pharmacia). Coupling was
achieved as described by the manufacturer. Thereafter the gel
was washed intensively with 1 mol/1 sodium chloride in 10
mmol/1 sodium phosphate containing 10 g/1 Triton XI00. The
α-bungarotoxin binding proteins were then eluted with 20 g/1
sodium dodecylsulphate (SDS), concentrated, and analysed un-
der non-reducing conditions by SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE).
SDS-PAGE of α-bungarotoxin binding proteins
Affinity purified α-bungarotoxin binding proteins were reduced
at 37 °C with 30 ml/l mercapt ethanol, then applied to a 10%
or 12.5-7.5% SDS-PAGE according to Laemmli (11). The
proteins were separated at a constant current of 50 mA for
2.5 h in a vertical gel electrophoresis system (VA 150; Desaga).
For the determination of protein size, high molecular mass
standard proteins (Gibco-BRL; Amersham & Buchler) were
run in parallel. Proteins were stained with 2 g/1 Coomassie Blue
(Merck).
Cross-reaction of α-bungarotoxin binding proteins
with myasthenia gravis patient sera
Labelled α-bungarotoxin binding components were obtained
from crude extracts of TE671 and IMR32 cells by gel filtration
as described above. Pooled peak fractions were used in an
immunoprecipitation assay with human myasthenia gravis sera.
[125I]a-Bungarotoxin-labelled complexes from TE671 or IMR32
cells were incubated for 6 h at 4 °C with 5 μΐ of myasthenia
gravis patient sera. Immunoprecipitation was done with an
equivalent volume of goat anti-human IgG's (Lawrence Lab-
oratories, Australia). The precipitates were pelleted by centrif-
ugation at 11000 g in an Eppendorf centrifuge, then washed
twice with 10 g/l Trition X-100 containing 10 mmol/1 sodium
phosphate buffer. The radioactivity was measured in a gamma
counter (Minaxi-gamma; Packard).
Purification of acetylcholine receptor from TE671
cells
For affinity chromatography of acetylcholine receptor from
TE671 and human muscle ecus, α-najatoxin was prepared from
crude snake toxin as described by Karlson & Widlund (12).
Acetylcholine receptor were purified according to the method
described by Katies & Kalden (13). Briefly, the α-najatoxin was
coupled to cyanogen bromide-activated sepharose (2 g/1 gel;
Pharmacia). Thereafter, cell extracts from TE671 cells or human
muscle tissue were loaded on the column. After removing un-
specifically bound proteins with 1 mol/1 sodium chloride, ace-
tylcholine receptors were eluted with 1 mol/1 carbamylcholine.
The purified acetylcholine receptors were labelled with [125I]a-
bungarotoxin in excess and used as antigens in a radioimmu-
noassay (RIA) as previously described (13, 14).
Concentrations of anti-acetylcholine receptor autoantibodies
given in nmol/1 were determined from the pelleted radioactivity
and are equally expressed as the number fo α-bungarotoxin
binding sites precipitated per litre of serum. For the calibration
of the RIA a control standard serum was used as previously
described (15).
Determination of cAMP
IMR32 or TE671 cells (5 χ ΙΟ4) were incubated for 30 min in
Dulbecco's modified Eagle's medium, supplemented with
1 mmol/1 3-isobutyl-l-methylxanthine (Sigma) to inhibit phos-
phodiesterases (16). Forskolin (Signia) was used in a concen-
tration of 100 μπιοΐ/ΐ for preincubation of cells for l h at 37 °C.
Immediately before stimulation, forskolin was removed by
washing cells twice with phosphate-buffered saline.
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For inhibition experiments, 5 χ ΙΟ4 cells of IMR32 or TE671
cells were preincubated with the indicated concentrations of
α-bungarotoxin (Serva). Acetylcholine receptors were stimu-
lated with 10 mmol/1 of the agonist carbamylcholine (Sigma)
in phosphate-buffered saline. After 30 min, cells were pelleted
and washed twice with ice-cold phosphate-buffered saline. The
reaction was stopped by adding 0.1 ml of 1.5 mol/1 perchloric
acid (16). After neutralisation the probes were centrifuged at
5000 g. The supernatants were collected, stored up to 4 weeks
at —70 °C or immediately tested for cAMP. cAMP was meas-
ured in duplicates (10 μΐ) according the method of Oilman (17)
using a commercial test kit (Amersham & Buchler).
Determinat ion of Ca2*-mobilization after cell st imu
lation
Cells (0.1 χ 1012/0 were loaded with indo-1-ester (acetoxyme-
thyl ester of l-[2-amino-5-(6-carboxyindol-2-yl)-phenoxy]-2-(2'-
armno-5'-methylphenoxy)-ethane-N,N,N^N'-tetraacetic acid,
50 μπιοΐ/ΐ; Calbiochem) and incubated for 20 rnin at room
temperature. Then the cell suspension was diluted 10-fold and
incubated for another 60 min. Thereafter cells were pelleted,
washed twice and resuspended in phosphate-buffered saline (ceil
count 10n/l) as described by Tsien & Rink (18). Fluorescence
before and during carbamylcholine stimulation was measured
in a spectrofluorometer (Perkin Elmer) with an excitation and
emission wavelength of 336 and 404 nm, respectively. As posi-
tive control 10-100 nmol/1 A23187 (Sigma) or 0.25-10 umol/1
ionomycin (Calbiochem) were added to the cell suspension.
[Ca2"1"]; was calculated as described previously (19, 20). Inhibi-
tion of [Ca2+]j was tested by preincubating cells with 1—10
μιηοΐ/ΐ α-bungarotoxin for 30 min or for l h with a 1:100 or
1 : 500 dilution of myasthenia gravis patient sera (n = 11) or a
serum obtained from a patient with Lambert-Eaton syndrome.
Sera from healthy donors (n = 5) were used in parallel as
controls.
Results
Gel filtration and affinity chromatography
of α-bungarotoxin binding proteins ex-
pressed by TE671 or IMR32 cells
By incubating various fractions of Triton-XlOO-sol-
ubilized membranes of IMR32 or TE671 cells with
[125I]a-bungarotoxin, followed by removal of unbound
α-bungarotoxin by Sephadex G50 gel filtration (fig.
1), it was found that IMR32 cells express about 4
times more α-bungar toxin-binding proteins than
TE671 cells (data not shown),
Fractions 17-22 of TE671 cells and fractions 19-24
of IMR32 cells contained the initial peak of radio-
activity representing α-bungarotoxin binding pro-
teins. The increase in radioactivity after fraction 25
for each cell line represents unbound ligands. From
the position of marker proteins the approximate mo-
lecular mass for α-b ngarotoxin binding proteins was
Μτ 160000 for IMR32 and Μτ 240000 for TE671
extracts. This value for TE671 corresponds to the
known molecular mass of the acetylcholine receptor
from human muscle (21).
40 45
Fraction no.
Fig. 1. α-Bungarotoxin binding proteins of TE671, but not
IMR32 cells, show the molecular mass of human ace-
tylcholine receptor in gel filtration experiments:
Triton X-100-solubilized extracts from IMR32 cells (2.5
χ 108; dashed line) or TE671 cells (5 χ ΙΟ8; solid line)
were incubated with [125I]a-bungarotoxin and submitted
to gel filtration on a Sephadex G50 column (flow rate:
20 ml/h). Radioactivity (counts/min) in 1 ml fractions
was measured by γ-counting.
Solid dots represent the position of marker proteins
(1 = apoferritin; 2 = -amylase; 3 = alcohol dehydro-
genase and 4 = albumin)
When α-bungarotoxin binding proteins from TE671
and IMR32 cells were affinity purified using α-bun-
garotoxin Sepharose 4B, then analysed with SDS-
PAGE (fig. 2a and 2b), it was shown that the a-
bungarotoxin binding protein of TE671 cells consisted
of subunits of Μτ 44000, 59000, 54000 and 68000,
which corresponds with the known characteristics of
the α-, β-, γ- and δ-subunits of the human muscle
nicotinic acetylcholine receptor (22). In contrast,
SDS-PAGE of the α-bungarotoxin binding protein of
IMR32 cells showed one strong subunit band at Mr
50 000 and some weaker bands with higher and lower
molecular masses. At present it is not clear whether
these bands represent various subunits or degradation
products.
Reactivity of α-bungarotoxin binding pro-
teins with myasthenia gravis patient serum
antibodies
Constant amounts of radiolabelled α-bungarotoxin
binding proteins from IMR32 and from TE671
(20000 counts per minute) were incubated with un-
diluted serum from myasthenia gravis patients. It was
demonstrated that almost all sera from patients with
myasthenia gravis precipitated high amounts of ra-
dioactively labelled α-bungarotoxin binding proteins
from TE671, but not from IMR32 (tab. 1). This
indicates that α-bungarotoxin binding proteins from
TE671 cells immunologically represent acetylcholine
receptor. This is not the case, however, for α-bungar-
otoxin binding proteins expressed on IMR32 cells.
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Fig. 2. Subunit composition of α-bungarotoxin binding proteins from TE671 corresponds to that of the human acetylcholine
receptor in SDS-PAGE:
α-Bungarotoxin binding proteins of TE671 (2a) and IMR32 (2b) cells were separated on SDS-PAGE (10% and 12.5-7.5%
gradient) under non-reducing conditions as described in Materials and Methods. Note that different sets of marker
proteins were used in figures 2a and 2b. The molecular masses are given.
Tab. 1. Cross-reactivity of myasthenia gravis patient sera with
α-bungarotoxin binding proteins from solubilized
TE671 and IMR32 cell extracts


























































[125I]a-Bungarotoxin-labelled cellular proteins (20000 counts/
min) were incubated with constant volumes of indicated sera
and thereafter precipitated with a goat anti-human IgG anti-
body. Radioactivity of immunoprecipitates was determined.
Mean values of duplicates are shown in counts per minute.
Sera which inhibit the increase in [Ca2+]i are indicated by A;
nd. = not determined.
Reactivity of myasthenia gravis patient
serum autoantibodies with affinity
chromatography-purified acetylcholine re-
ceptor from TE671 cells and human muscle
tissue
When affinity chromatography-purified acetylcholine
receptor from TE671 cells and muscle tissue were
tested in a fluid phase radioimmunoassay as described
(14—15), there was a very good correlation (r = 0.96)
with the autoantibody concentrations (nmol/1) in 66
sera of patients with myasthenia gravis (fig. 3). This
is further evidence for the expression of an imrnuno-
logically identical acetylcholine receptor on TE671
cells, compared with that on human muscle tissue.
No such correlation could be demonstrated when a-
bungarotoxin binding proteins from IMR32 cells were
used as substrate for this assay.
Changes in intracellular cAMP concentra-
tions after stimulation with carbamylcholine
To test whether the α-bungarotoxin binding proteins
on TE671 and IMR32 cells represent functional ace-
tylcholine receptor, different intracellular second mes-
senger mechanisms in carbamylcholine stimulated
cells were investigated. Two different assays were used
to test signal transduction in TE671 and IMR32 cells:
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1) changes in intracellular cAMP concentrations, and
2) the increase in intracellular Ca24" concentrations
No significant increase of cAMP in either of the tested
cells were observed after stimulation with carbamyl-
choline. However, when TE671 cells were preincu-
bated for l h with 100 μιηοΐ/ΐ forskolin, which is
known to be a potent adenylate cyclase activator,
cAMP concentrations increased to approximately
1 30% compared with unstimulated cells. This increase
was blocked by oc-bungarotoxin (fig. 4a) and was
enhanced when TE671 cells were grown in dexameth-
asone (fig. 4b). In contrast, no increase of cAMP in
IMR32 cells was obtained after stimulation with car-
bamylcholine, no matter what culture conditions were
used (with or without forskolin or dexamethasone;
data not shown).
These observations indicate that carbamylcholine
treatment stimulated an increase of cAMP in TE671
cells under certain conditions. It is likely that this
effect is mediated through a human acetylcholine re-
ceptor expressed on TE671 cells. In contrast, no such
effect was observed with IMR32 cells. The increasing
effect of dexamethasone treatment in TE671 cells is
consistent with experiments by Luther & Lindstrom
who described an increase of acetylcholine receptor
10 20 30 40
Anti -acety lchol ine receptor antibody
titre [nmol/l]; muscle tissue
50
Fig. 3. Correlation of reactivity of sera from patients with
myasthenia gravis towards affinity acetylcholine recep-
tor from human muscle or TE671 cells:
Sera from 66 patients with myasthenia gravis were tested
for their autoantibody concentration against acetylcho-
line receptor from TE671 cells (y-axis) and muscle tissue
(x-axis) in a RIA. The presented data represent the
mean value of duplicates in the RIA. The correlation







































Fig. 4. Stimulation with carbamylcholine increases cAMP con-
centrations in TE671 cells:
Figure 4a gives data obtained without dexamethasone,
figure 4b with the addition of 2 μηιοΐ/ΐ dexamethasone
to the medium. Columns 1 to 5 represent results with
forskolin, columns 6 to 10 after preincubation of TE671
cells with 100 μπιοΐ/ΐ forskolin.
dl unstimulated cells; ϋϋΠ cells stimulated with 10
mmol/1 carbamylcholine; E=l carbamylcholine-stimu-
lated cells preincubated with 100 μηιοΐ/ΐ α-bungaro-
toxin; DDU carbamylcholine-stimulated cells preincu-
bated with 10μηιο1/1 α-bungarotoxin; ES3 carbamyl-
choline stimulated cells preincubated with 1 μηιοΐ/l α-
bungaro toxin.
In all experiments TE671 cells were grown in RPMI
medium supplemented with 1 mmol/1 isobutylme-
thylxanthine to inhibit phosphodiesterases.
surface expression in TE671 cells after dexamethasone
exposure (22). Similar results were reported by Kaplan.
& Blau on cultured human muscle cells (23).
Increase of [Ca2 + ]i in TE671 cells after stim-
ulation with carbamylcholine
A significant increase in [Ca2+]i was observed in
TE671 cells after stimulation with various concentra-
tions of carbamylcholine. This agonist-mediated in-
crease of [Ca2"h]i was completely blocked by the pre-
incubation of TE671 cells with α-bungarotoxin (tab.
2). No [Ca2+]i increase was observed in IMR32 cells
(data not shown).
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Autoant ibodies in some sera of myasthenia
gravis patients inhibit the carbamylcholine-
induced increase of [Ca2+]j in TE671 cells
Sera of 11 patients with myasthenia gravis were tested
for their ability to inhibit carbamylcholine-induced
increases in [Ca2+]j in TE671 cells. In 4 of these patient
sera we found a dose-dependent inhibition of maximal
[Ca2+]i to about 50% (fig. 5a-d). Interestingly, the
serum of a patient with Lambert-Eaton syndrome was
also able to suppress the increase in [Ca2+]j (fig. 5e).
The fact that this patient's serum was negative in
conventional radioimmunoassay for the presence for
anti-acetylcholine receptor antibodies is consistent
with reports by Sher & dementi (24) suggesting that
Lambert-Eaton syndrome patient sera contain auto-
antibodies reacting with calcium channels. No inhi-
bition of the carbamylcholine-induced increase in
[Ca2+]i in TCE671 cells was found when sera from
healthy donors (n = 5) were used (fig. 5f). None of
the other tested sera from myasthenia gravis patients
(n = 7) showed any inhibition of the calcium re-
sponse. There was no correlation between acetylcho-
line receptor antibody titres in myasthenia gravis pa-
tient sera and their correlation to inhibit the calcium
response. This might be due to the fact that autoanti-
bodies against the acetylcholine receptor are directed
against different epitopes of the receptor complex (25,
26) and might therefore differ in their functional ca-
pabilities.
Tab. 2. Carbamylcholine-induced acetylcholine receptor acti-






























INDO-1 loaded TE671 cells were stimulated with ionomycin
and Carbamylcholine in indicated concentrations. [Ca?+]i was
determined as described in Material and Methods using a
spectrofluorometer. Maximal values for [Ca2+]j after stimula-
tion with the indicated stimuli are given. For inhibition exper-
iments cells were preincubated with oc-bungarotoxin for 30 min
at 37 °C in indicated concentrations.
a Figures are given in nmol/1. Results of one out of four
independent experiments are shown.
Discussion
The binding of the snake venom α-bungarotoxin is a
characteristic property of the human acetylcholine
receptor. In this paper we describe two human tumour






5 0 5 0
t [Mini
Fig. 5. Myasthenia gravis and Lambert-Eaton syndrome patient sera inhibit Ca2+-mobilization in TE671 cells after stimulation
with Carbamylcholine:
Serum dilutions of 1 :100 (dashed line) and 1:500 (solid line) from patients with myasthenia gravis (a-d) and one
patient with a Lambert-Eaton syndrome (e) and serum of a healthy donor (f) were preincubated with TE671 cells. Untreated
TE671 cells were used as controls (dotted line). [Ca2^ was measured after stimulation with 25 mmol/1 carbamylcholine
as described. Carbamylcholine was added at l min and is indicated (Δ).
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α-bungarotoxin in vitro. One of these cell lines,
TE671, which was originally described as a medullo-
blastoma cell line (7), is derived from a rhabdomy-
osarcoma (8). The second cell line investigated,
IMR32, originates from a human neuroblastoma (10).
Applying gel filtration techniques, the α-bungarotoxin
binding protein from TE671 cells exhibited a consider-
ably higher molecular mass than the oc-bungarotoxin
protein isolated from IMR32 cells. When a-bungaro-
toxin binding proteins from the two cell lines were
analysed by SDS-PAGE, the molecular mass and
subunit composition of the α-bungarotoxin binding
structure from TE671 cells showed a similar pattern
to that known for the nicotinic acetylcholine receptor
isolated from human muscle (21). The acetylcholine
receptor purified from TE671 consists of subunits of
Μτ 44000, 50000, 54000 and 68000, which is consis-
tent with the known characteristics of the α-, β-, γ-
and δ-subunits of the human muscle nicotinic acetyl-
choline receptor. In contrast, the α-bungarotoxin
binding protein from IMR32 cells showed a distinct
pattern of one strong band at MT 50 000 accompanied
by weaker bands with higher and lower molecular
masses. At present it is not clear if these differences
in the protein pattern are due to the presence of
different receptor subunits or degradation products.
When the immunological cross-reactivity was tested
using sera from myasthenia gravis patients, a high
cross-reactivity was found between a-bungarotoxin
binding proteins from TE671 cells and human muscle
acetylcholine receptor, whereas no cross-reactivity
was found when α-bungarotoxin binding proteins
from IMR32 cells were used as antigen. These data
suggest that the α-bungarotoxin binding protein ex-
pressed on TE671 cells represents biochemically and
imrnunologically intact human nicotinic acetylcholine
receptors. This is apparently not true for the α-bun-
garotoxin binding protein from IMR32 cells.
In additional studies, second messenger mechanisms
in TE671 cells and IMR 32 cells were tested after the
cells had been stimulated with the acetylcholine re-
ceptor agonist c rbamylcholine. In TE671 cells, an
increase in cAMP concentrations was induced by c r-
bamylcholine, but only when cells were pretreated
with forskolin. This effect was inhibited by the addi-
tion of various concentrations of α-bungarotoxin. In
addition, there was a pronounced increase in intra-
cellular cAMP concentrations in cells grown in media
supplemented with dexamethasone, which is known
to induce and increase the acetylcholine receptor ex-
pression (22, 23). No increase in cAMP was seen in
identically treated IMR32 cells.
As another mechanism of intracellular signal trans-
duction, changes in [Ca2+]j were determined after
stimulation of TE671 cells with c rbamylcholine. The
resulting increase [Ca2"f]i showed a maximum about
one minute after stimulation with c rbamylcholine,
and this increase was inhibited by the addition of a-
bungarotoxin. These data suggest the presence of a
functional acetylcholine receptor on TE671 but not
on IMR32 cell lines. Safran & Fuchs described phos-
phorylation of Torpedo californica-άζτινζά acetylcho-
line receptor by a Ca2"1"-dependent protein kinase C
(27). The stimulation of acetylcholine receptor leads
to the action of protein kinase and a cAMP-dependent
protein kinase, followed by a desensitization of recep-
tors (28, 29). Therefore, the agonist-induced decrease
in channel currents of muscle nicotinic acetylcholine
receptor may be related to intracellular Ca2+ concen-
trations (30). All these findings support the role of
Ca2+ and cAMP in the muscle activation process. In
one part of our experiments we measured an increase
in intracellular Ca2"1" after stimulation of TE671 cells
with the agonist c rbamylcholine. Whether this in-
crease in [Ca2*]! is caused by external Ca2+ influx or
by release from intracellular stores remains to be
investigated.
In addition, Bencheriff & Lukas described the exis-
tence of muscarinic acetylcholine receptors on the
TE671 cell line (31). However, it is unlikely that the
[Ca2+]i increase in TE671 cells is mediated through
muscarinic acetylcholine receptor, because this should
not be blocked by α-bungarotoxin. Many questions
remain concerning signal transduction pathways in
malignant cell lines. For example Morris & Newsom-
Davis described two α-subunit isoforms of the acetyl-
choline receptor in TE671 cells (32). A differential
expression of these isoforms therefore may lead to an
altered intracellular signal transduction pathway.
To investigate the role of acetylcholine receptor-func-
tion-inhibiting autoantibodies, we preincubated
TE671 cells with myasthenia gravis patient sera prior
to stimulation with c rbamylcholine. Four out of 11
myasthenia gravis patients sera had an inhibiting ef-
fect on the maximal amplitude and duration of [Ca2"*"]j
increase in TE671 cells. However, no correlation could
be obtained with acetylcholine receptor serum anti-
body titres. This finding could be explained by the
well documented effect that acetylcholine receptor
directed antibodies in myasthenia gravis patients sera
are characterized by a considerable heterogeneity in
terms of their reactivity to different epitopes on var-
ious subunits of the acetylcholine receptor. This ob-
servation is also in agreement with data published by
Lang & Newsom-Davis (33), who demonstrate that
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acetylcholine receptor antibodies inhibiting Na"*" in-
flux in stimulated TE671 cells were present in only
about 30% of myasthenia gravis patients' sera (34).
Interestingly, the serum from one patient with a Lam-
beri-Eaton symdrome also showed an inhibitory effect
on the intracellular Ca2+ response in carbamylcho-
line-stimulated TE671 cells. This patient serum did
not contain any detectable anti-acetylcholine receptor
antibodies, which is in concordance with a report by
Sher & dementi (24) who described specific antibod-
ies against Ca2+-channels in sera of Lambert-?Eaton
patients, with the functional capacity to cause myas-
thenia gravis-like symptoms.
In summary, our data suggest that the oc-bungaro-
toxin-binding proteins in TE671 cells represent im-
munologically and functionally intact human nico-
tinic acetylcholine receptors. Therefore, TE671 cells
are not only useful for the isolation of acetylcholine
receptors, but also for functional studies on the effects
of various types of anti-acetylcholine receptor anti-
bodies in myasthenia gravis patient sera. It remains
to be ascertained whether the observation that about
one third of myasthenia gravis patient sera were cap-
able of modulating second messenger pathways in the
TE671 cell line is of clinical relevance.
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